Metrics cut 1
- FY27-28 consolidated EBITDA margin guidance cut to 25-27% (from earlier expectations of 30%+)
Event Participants
Executives
1 Punit Rasadia, Chairman & Managing Director
Analysts
7 Anshul Sharma, Deepak Poddar, Gaurav Shukla, Majid Ahmed, Paras Chheda, Vaibhav Mishra, Varsha Chandrani, Vikas Daga, Virat Shah
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Total Income (Consolidated) | ₹87.62 crores | Up from ₹33.31 crores YoY; driven primarily by consolidation of acquisitions (Apiqo, Bizotic, Remember India) plus organic growth |
| EBITDA | ₹15.65 crores | Up from ₹6.26 crores YoY; margin compressed to ~17% due to spike in raw material prices from geopolitical tensions and Remember India integration costs |
| Profit After Tax | ₹8.28 crores | Up from ₹3.55 crores YoY; pressure from Remember India depreciation and maintenance costs |
| EBITDA Margin | ~17% | Down from ~19% YoY; impacted by 2-3x rise in solvent/petroleum-based raw material prices and Remember India's investment phase; management guiding recovery to 25-27% |
| Installed Manufacturing Capacity | 1,400-1,600 MTPA | Post-acquisition capacity including Anlon (~400 MT), Apiqo, Bizotic, and Remember India |
| Capacity Utilization (Consolidated) | 62-70% | Anlon standalone at peak; Bizotic and Apiqo have room to increase gradually |
| Capex (New Expansion) | ~₹130 crores | For Anlon standalone capacity addition (~1,200 MT) funded by ~₹70 crores debt at 8.5-8.6% interest and internal accruals |
Geographic & Segment Commentary
- Anlon Standalone (APIs & Intermediates): Revenue of ~₹32 crores in Q1 FY27, slightly down from ₹33 crores YoY; company is at peak capacity utilization, limiting production growth in Q1 due to product mix and production cycles of 15-40 days. Expected to report ~₹180 crores for FY27.
- Apiqo Organics (Fine & Specialty Chemicals): Revenue of ~₹45 crores in Q1 FY27; fully booked/overbooked for industrial and fine chemicals. FY27 contribution guided at ₹120-150 crores; considered independently sustainable with better profitability.
- Bizotic Lifescience (Manufacturing Platform): Revenue of ~₹12 crores in Q1 FY27; profitable at current utilization. FY27 contribution guided at ~₹60 crores; provides ready-to-operate facility supporting regulatory readiness.
- Remember India Health Links (Finished Dosage Formulation): In investment/turnaround phase with no revenue expected until Q4 FY27; undergoing upgradation and validation activities. WHO-GMP approval expected by end of calendar year 2026; strategy includes CDMO projects and regulatory market access, leveraging Anlon's backward API supply chain.
- New Subsidiaries (Anlon Biologics & Anlon Medicare): Anlon Biologics incorporated for peptides, biosimilars, and bioproducts manufacturing; construction to commence within 2 months, revenue expected by Q4 FY28. Anlon Medicare for surgical implants (trauma, spine, joints), aligned with pain management ecosystem; revenue expected by Q2 FY28.
Company-Specific & Strategic Commentary
- Acquisition of Remember India Health Links: Completed 8 May 2026, acquiring 63.98% stake; marks entry into finished dosage formulations (tablets, capsules, ointments) with access to 30+ formulation dossiers. Transition from API-focused manufacturer to integrated pharmaceutical company across B2B APIs, domestic retail, and hospital markets.
- Backward Integration via Apiqo Organics: Strengthens critical pharmaceutical intermediate capabilities and establishes industrial and fine chemical business; supports cost competitiveness and supply security.
- Capacity Expansion & Capex: ~₹130 crore capex underway to expand standalone Anlon capacity from ~400 MT to ~1,600 MT (adding ~1,200 MT) with 8 new clean lines for simultaneous API manufacturing; commissioning expected by Q1 FY28, subject to statutory approvals; FY28 revenue guided at ~₹700 crores based on 50-60% utilization of new capacity.
- CDMO & Regulatory Pipeline: CDMO commercial supply for one molecule expected post-Q3, two other molecules in process validation; 7 new API DMF filings planned within FY27 with compilation activities ongoing.
- New Product Development: Peptide manufacturing products (human, cosmetic, nutra) developed at R&D level; pain management ointment (first-in-India, Volini-competitive) submitted for DCGI approval, expected within one year; will be manufactured in-house via Remember India.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| FY27 Revenue | ₹350-400 crores | Includes Anlon ( |
| FY28 Revenue | ~₹700 crores | Based on new greenfield capacity assuming 50-60% utilization; subject to timely statutory approvals and commissioning |
| EBITDA Margin | 25-30% in Q2-Q3 FY27; ~25% for FY27, 25-27% | Q2 expected better than Q1; recovery driven by price pass-through to customers and RM stabilization; consolidated margin impacted by fine chemicals segment (lower margin) and Remember India turnaround |
| PAT Margin | 12-13% for FY27 and FY28 | Conservative estimate given new capex execution risks; Q1 FY27 PAT margin ~9.5% |
| Revenue CAGR (Mid-term) | ~30% over 3 years | Supported by expanded manufacturing platform, regulatory capabilities, diversified product portfolio, and acquisitions |
| Cash Flow | Positive operating cash flow expected by FY27-end | Working capital improvement via stricter payment terms (reducing from 130-135 days receivables toward 90-day terms); inventory investment for DMF validations not a cash flow concern |
Risks & Constraints
| Risk | Context |
|---|---|
| Raw Material Price Volatility | Solvent and petroleum-derived raw material prices increased 2-3x following geopolitical tensions (e.g., methanol from ₹22 to ₹58-60). Prices changing every hour; management doing one-time price revisions with customers but cannot renegotiate daily in B2B relationships. Mitigation: committed volume contracts with credible customers; recovery expected as geopolitical situation stabilizes |
| Remember India Turnaround Execution | Remember India in investment/validation phase with no revenue contribution until Q4 FY27; depreciation and maintenance costs (~₹1.29 crore) impacting consolidated PAT. WHO-GMP approval expected by end of CY26; execution risk in regulatory approvals and commercial ramp-up |
| Capacity Expansion Delays | ₹130 crore capex dependent on statutory approvals; management flagged potential delays could push commissioning beyond Q1 FY28 and impact FY28 revenue guidance of ₹700 crores |
| Margin Dilution from Mix | Fine chemicals (Apiqo) carry lower EBITDA margins than pharma; consolidation drags group margin to 25-27% vs earlier 30%+ expectations. Employee costs increasing due to professional hiring |
| Customer Concentration | B2B model with 10-15 customers; management must maintain credibility on pricing, cannot pass on cost increases immediately; pressure on near-term margins |
| Currency & Freight Cost Fluctuations | USD moved from 91 to 96 in one month; freight costs also impacting raw material prices, indirect exposure to crude oil via solvents (40% of API manufacturing cost) |
Q&A Highlights
Margin Pressure & Recovery Timeline
Question: RM prices increased 2-3x; what's the current situation and when will margins normalize? (Unidentified Analyst)
Answer: Prices not normalized and depend on global war situation; price revisions already implemented with customers, with reflection expected in next 1-2 quarters. Q2 margins expected better than Q1; EBITDA margin guided to 25-30% range in Q2-Q3 FY27. (Punit Rasadia)
Sustainability of Margin Decline & FY27 Consolidated Margins
Question: Margins declining for two consecutive quarters despite prior guidance of 24-25% floor; how should investors think about FY27 consolidated margins? (Vaibhav Mishra)
Answer: Q1 pressure temporary due to geopolitical situation and legacy orders at old prices; long-term customer relationships prevented immediate price hikes. Remember India in investment phase with depreciation drag; Apiqo and Bizotic profitable but diluting margin percentage. FY27 consolidated EBITDA margin guided at 25%, with 25-27% expected as sustainable. (Punit Rasadia)
Revenue Breakdown by Entity - FY27 vs FY28
Question: What will be revenue contribution from subsidiaries for FY27 and FY28? (Paras Chheda)
Answer: FY27: Anlon ~₹180 crores, Apiqo ₹120-150 crores, Bizotic ~₹60 crores; Remember India not included. FY28: ~₹700 crores total; management declined to provide subsidiary-level split for FY28, will share exact projections in Q2 call. (Punit Rasadia)
Optimal Capacity Utilization vs Peak Revenue
Question: At current consolidated capacity utilization (62-65%), what is peak revenue potential? (Deepak Poddar)
Answer: Peak revenue at current capacity is ₹350-400 crores at 65-67% utilization; production cycles vary by product (15-40 days), so quarter-on-quarter comparisons are not meaningful; H1 vs H2 comparison recommended. (Punit Rasadia)
Funding/Working Capital & Cash Flow Positivity
Question: With margin compression and high working capital days, will there be cash flow issues? Will a fundraise be needed to support ₹700 crore revenue? (Paras Chheda)
Answer: Inventory is an investment for DMF filings (validation batches held 9-12 months), not a cash flow problem. Payment terms tightened with customers; average receivables at 130-135 days vs 90-day terms. Expecting positive (though lower) operating cash flow by FY27-end; working capital days to reduce by 60-70 days. (Punit Rasadia)
New Subsidiaries - Anlon Biologics & Anlon Medicare
Question: What is the purpose and revenue timeline for these subsidiaries? (Anshul Sharma)
Answer: Anlon Biologics for peptides, biosimilars, and bioproducts—kept separate due to different manufacturing and regulatory requirements (chemical vs biological); construction to start within 2 months; revenue expected Q4 FY28. Anlon Medicare for surgical implants (trauma, spine) aligned with pain management ecosystem (Ketoprofen, Loxoprofen); revenue expected by Q2 FY28. (Punit Rasadia)
PAT Margin Expectations
Question: Given higher depreciation and interest costs, what PAT margin should investors expect for FY27 and FY28? (Varsha Chandrani)
Answer: PAT margin guided at 12-13% for both FY27 and FY28, conservative given capex execution risks and potential statutory approval delays. (Punit Rasadia)
CDMO Updates & New Product Launches
Question: Status of CDMO commercial supply and peptide/pain management products? (Ashish Parikh)
Answer: CDMO process validation ongoing; one molecule commercial supply post-Q3. Peptides—Anlon Biologics incorporated; most products developed at R&D; FY28 manufacturing target. Pain management ointment (first-in-India, Volini-competitive) to be submitted to DCGI; approval expected within a year; will manufacture in-house via Remember India. (Punit Rasadia)
Key Takeaway
Anlon Healthcare reported Q1 FY27 consolidated revenue of ₹87.62 crores (vs ₹33.31 crores YoY), EBITDA of ₹15.65 crores, and PAT of ₹8.28 crores, with EBITDA margin compressing to ~17% due to 2-3x raw material price inflation and Remember India Health Links integration costs. The quarter marked a strategic transformation—completing the Remember India acquisition (63.98% stake) for entry into finished dosage formulations, alongside Apiqo and Bizotic acquisitions, expanding manufacturing capacity to 1,400-1,600 MTPA. Management guided FY27 revenue of ₹350-400 crores (excluding Remember India), EBITDA margin recovery to 25-27% by Q3, and FY28 revenue of ~₹700 crores backed by a ₹130 crore capex (funded with ₹70 crores debt at ~8.6%) for 1,200 MT new capacity, commissioning by Q1 FY28. PAT margin guided at 12-13% for FY27/28. Risks include continued raw material volatility, Remember India regulatory approvals, and potential capex delays. New ventures—Anlon Biologics (peptides) and Anlon Medicare (surgical implants)—target revenue from FY28/Q4 FY28, with CDMO commercial supply expected post-Q3 and seven new API DMF filings planned within FY27. Management remains confident of delivering 25%+ consolidated EBITDA margins as price revisions flow through, with a 30% revenue CAGR target over three years.